Study Looking at a Treatment for Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

What we are studying

The purpose of this study is to evaluate the effects of dasatinib when added to the regular chemotherapy medicines to treat pediatric patients with newly diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia.

Who we are studying

  • Men and Women
  • Races:
    • White
    • African American
    • Asian
    • American Indian or Alaska Native
    • Native Hawaiian or Pacific Islander
    • Other
  • All Ethnicities
  • Ages 1 - 18

Eligibility Criteria

  • Philadelphia chromosome-positive ALL

What is involved

  • You will receive dasatinib study drug starting within 14 days after you begin treatment for your disease. Dasatinib should be taken by mouth once per day
  • Every day and continued throughout the study. If your doctor recommends a bone marrow or stem cell transplant your dasatinib treatment will be stopped before the transplant takes place.
  • After you have adequately recovered from the transplant procedure you may be offered the option to receive more dasatinib for up to 2 years from your first dose.

Compensation

None

Contact Information

Study Coordinator
Graham Keyes
Email
grkeyes@wakehealth.edu
Phone
336-716-9027

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.